SCHEDULE: Adage Capital Discloses 5.82% Stake in Relmada Therapeutics

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.82% beneficial ownership in Relmada Therapeutics, Inc. common stock.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 4,270,000 shares of Relmada Therapeutics, Inc. common stock.
• This ownership represents 5.82% of the company's outstanding common stock.
• The percentage is calculated based on 73,333,622 shares of common stock outstanding as of November 10, 2025, as reported in Relmada's Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• The reporting persons share both voting and dispositive power over these 4,270,000 shares.
• The Schedule 13G filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Relmada Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has disclosed a substantial stake, implying confidence in the company's prospects without indicating any immediate operational changes or financial performance.

Positives

• A significant institutional investor, Adage Capital Management, L.P., has taken a substantial 5.82% stake in Relmada Therapeutics, Inc., potentially signaling confidence in the company's future prospects.
• The filing explicitly states that the shares were acquired in the ordinary course of business, suggesting a long-term investment perspective rather than an activist or control-seeking stance.

Future Outlook

This filing does not contain forward-looking statements or guidance from Relmada Therapeutics, Inc. It is a disclosure of beneficial ownership by an institutional investor group.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G can indicate increased investor interest in the biotechnology and pharmaceutical sectors, particularly for companies like Relmada Therapeutics, Inc. that may be developing new treatments. A significant stake by a reputable investment manager like Adage Capital Management could be viewed positively by the market, suggesting a belief in the company's long-term potential or specific pipeline assets, contrasting with general market sentiment or competitor performance.

Comparison to Industry Standards

• A 5.82% stake by an institutional investor like Adage Capital Management is a substantial position, often seen as a vote of confidence. For example, similar significant stakes by funds in emerging biotech firms such as those seen with ARK Invest's positions in CRISPR Therapeutics or Beam Therapeutics often precede increased market attention.
• While not a direct comparison of financial performance, the entry or increase of a position by a major fund can be benchmarked against other institutional holdings in the sector. For instance, a comparable percentage holding in a company of similar market capitalization to Relmada Therapeutics by a top-tier hedge fund would typically be considered a notable event.

Stakeholder Impact

• Shareholders: May view the significant institutional ownership as a positive indicator, potentially increasing investor confidence and attracting further investment.
• Employees: No direct impact mentioned, but increased investor confidence could indirectly support company stability and future growth initiatives.
• Customers/Suppliers/Creditors: No direct impact mentioned, as this filing pertains to ownership structure rather than operational or financial performance.

Key Dates

Recommendation

The disclosure of a 5.82% stake by Adage Capital Management, L.P. in Relmada Therapeutics, Inc. is a positive signal, indicating institutional confidence. However, this filing does not provide new operational or financial performance data to warrant an immediate 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental updates from the company to assess the long-term implications of this significant ownership.

Keywords

Relmada Therapeutics, Adage Capital Management, Institutional Ownership, Schedule 13G, Common Stock, Investment Management, Biotechnology, Pharmaceuticals